Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $0.78.

  • Amphastar Pharmaceuticals' Debt to Equity fell 430.64% to $0.78 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.78, marking a year-over-year decrease of 430.64%. This contributed to the annual value of $0.82 for FY2024, which is 1092.94% down from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Debt to Equity is $0.78, which was down 430.64% from $0.8 recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Debt to Equity high stood at $1.07 for Q3 2023, and its period low was $0.08 during Q2 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Debt to Equity averaged around $0.52, with its median value being $0.78 (2025).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Debt to Equity skyrocketed by 61618.51% in 2023, and later plummeted by 2358.49% in 2024.
  • Amphastar Pharmaceuticals' Debt to Equity (Quarter) stood at $0.17 in 2021, then fell by 16.92% to $0.14 in 2022, then soared by 542.83% to $0.92 in 2023, then fell by 10.93% to $0.82 in 2024, then dropped by 4.53% to $0.78 in 2025.
  • Its last three reported values are $0.78 in Q3 2025, $0.8 for Q2 2025, and $0.8 during Q1 2025.